Biotechnology Industry
Filter News
Found 44,406 articles
-
The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023. -
Burning Rock Announces Receipt of Notification from NASDAQ - Jan 04, 2024
1/4/2024
Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450.
-
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
1/4/2024
Laekna announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah.
-
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis. -
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months. -
The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools. -
2024 Predictions for Biotech M&As
1/3/2024
Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace. -
The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys. -
Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news. -
It wasn't a merry end to 2023 for Amgen or Zealand Pharma, which received Complete Response Letters for Lumakras and for dasiglucagon in congenital hyperinsulinism. -
Agios Pharmaceuticals met the primary endpoint in a late-stage trial investigating its drug mitapivat in treating adults with non-transfusion-dependent alpha- or beta-thalassemia. -
Anavex Life Sciences' stock dropped by more than a third in value on Tuesday after results for a Phase II/III Rett syndrome study failed to impress investors. -
Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront. -
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
-
Entrada Therapeutics Promotes Nathan J. Dowden to President
1/3/2024
Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
-
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Amicus Therapeutics announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.
-
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
1/3/2024
Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.
-
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
1/3/2024
ABVC BioPharma, Inc. and its subsidiary BioLite, Inc. announced that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc., as its first milestone payment under a global licensing agreement.
-
BioCentriq® Announces the Successful Completion of $29.2M Series A Further Strengthening Cell Therapy Contract Development and Manufacturing Services
1/3/2024
BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization, proudly announces the successful completion of its latest round of fundraising, securing $29.2M in capital investment.
-
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
1/3/2024
Dyne Therapeutics, Inc. announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.